表紙
市場調査レポート

多発性骨髄腫治療薬の世界市場およびパイプライン分析 (2015年)

Global Multiple Myeloma Drug Market & Pipeline Insight 2015

発行 KuicK Research 商品コード 330363
出版日 ページ情報 英文 415 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
多発性骨髄腫治療薬の世界市場およびパイプライン分析 (2015年) Global Multiple Myeloma Drug Market & Pipeline Insight 2015
出版日: 2015年05月14日 ページ情報: 英文 415 Pages
概要

世界各地で多発性骨髄腫の患者数が増加していますが、まだ有効な治療薬が開発・上市されていません。現在のところは化学療法が最も有効な治療法ですが、幹細胞移植や遺伝子組み換え型たんぱく質の活用も検討が進められています。今後は、薬剤開発の進展と共に候補薬パイプラインも強化され、市場も拡大していくと期待されています。

当レポートでは、世界各国における多発性骨髄腫治療薬市場の動向、およびパイプライ製品の開発状況について分析し、多発性骨髄腫治療薬の特性や作用機序、全体的な市場構造・動向、パイプライン製品の現在の開発状況、製品単位 (計40製品) および治験段階別の詳細な開発状況、上市済み製品 (計9製品) の販売状況、今後の市場の方向性といった情報をお届けいたします。

第1章 多発性骨髄腫の概略

第2章 多発性骨髄腫治療薬の作用機序

第3章 世界の多発性骨髄腫治療薬市場の分析

  • 現在の市場シナリオ
  • 多発性骨髄腫の治療薬の臨床パイプラインの概要

第4章 世界の多発性骨髄腫治療薬市場のダイナミクス

  • プラスに働いている市場パラメーター
  • 商業化に向けた課題

第5章 世界の多発性骨髄腫治療薬市場の将来展望

第6章 世界の多発性骨髄腫治療薬の臨床上の考察:企業別・適応症別・相別

  • 研究段階
  • 前臨床
  • 臨床
  • 第I相
  • 第I/II相
  • 第II相
  • 第III相
  • 認証前

第7章 上市済みの多発性骨髄腫治療薬の臨床上の考察

  • ベンダムスチン (Innomustine® Levact®, Treanda® & Treakisym®)
  • ボルテゾミブ (Velcade®)
  • カルフィルゾミブ (Kyprolis®)
  • ドキソブリシン・リポソーム - ALZA
  • インターフェロンα2b (Intron® A)
  • レナリドマイド(Ladevina® & Revlimid®)
  • ポマリドマイド (Imnovid® & Pomalyst®)
  • サリドマイド (Thaled®, Thalidomide Celgene™ & Thalomid®)
  • ゾレドロン酸 (Zometa®)

第8章 治験が中止・延期された、臨床パイプライン上の多発性骨髄腫治療薬

  • 開発報告の無いもの
  • 治験中止
  • 治験延期

第9章 競合環境

  • AbbVie
  • Altor BioScience
  • Astellas Pharma
  • Astex Pharmaceuticals
  • Benovus Bio
  • Biogen Idec
  • Bristol-Myers Squibb
  • Celegen Pharmaceuticals
  • Cleave Biosciences
  • Genmab
  • Novartis
  • Onyx Pharmaceuticals
  • Pfizer
  • Millennium Pharmaceuticals
  • Vaxil Biotherapeutics

図表一覧

目次

Multiple myeloma incidences are increasing across the globe and presently available therapeutics are unable to offer effective clinical benefits. Multiple myeloma chemotherapeutics shows modest pharmacological efficacy due to which necessity for better options are required. Surgery and radiation are equally ineffective and they are not viable for most of the cases. Pharmaceutical companies have identified this scenario due to which they are investing more funds in research and development segment. As a result, investigators would be able to screen more lead molecules for their safety and efficacy in multiple myeloma. Innovative modalities are being studied in clinical trial and they are expected to yield significant results thereby surpassing the issues related with presently available modalities in coming years.

In past few decades several methods for treatment of multiple myeloma has been developed by investigators. Surgery could be performed for transplanting bone marrow from healthy donor. Radiation therapy has modest effect because myeloma cells are spread throughout the body which means higher dosage are required. Chemotherapeutics have been used successfully in past few decades for multiple myeloma treatment. New modalities are being tried by investigators to decrease its morbidity and mortality rates. They are also expected to have lesser side effects and would be able to increase average survival rates. Several innovative multiple myeloma therapeutics is available in market which offers higher safety and efficacy levels. It is expected that new innovative therapeutics would be able to offer better pharmacological benefit to patients and generate significant revenues in coming years.

Stem cell transplant has been suggested by investigators as an effective way to treat multiple myeloma. These cells have capability to differentiate according to the environment in which they have been place. External cues can also be used to transform them into desired type before implanting in the body. Some researchers have proposed the use of recombinant proteins to be implanted in the bone marrow which will prevent the proliferation of multiple myeloma. More time is required to develop and refine this technology which could potentially eliminate multiple myeloma from the body. Such technologies are still under different phases of development and they are expected to take some time before entering in global market. These modalities are expected to change the way multiple myeloma is treated but lots of progress has yet to be made by investigators.

Monoclonal antibodies (mAbs) have been successfully used for the several malignancies due to their superior therapeutic efficacy and high specificity. Targeted mAbs have the ability to bind to specific cells due to which minimized side effects are observed in cancer patients. Investigators are also trying to develop targeted mAbs for treating multiple myeloma which would be offer better therapeutic effects. New modalities like cancer vaccines are also under investigation for studying their pharmacological efficacy. Vaccines for multiple myeloma are under investigation and they are expected to overcome relapse because they activates the patient's immune system. Important part of developing such vaccines is to carefully choose the correct candidate for long-term efficacy. They are also at different stages of clinical trials and strong clinical data is required before their marketing approval in coming years.

Several new developments are expected to take place in field of multiple myeloma segments in coming years. Technological advancements along with rising funding levels is expected to increase the rate of innovations for the development of multiple myeloma drug. As a result, their pipeline is expected to become strong and more clinical trials across the globe are expected to be instigated. Positive outcomes are expected from these clinical trials due to which volume of multiple myeloma therapeutics is going to increase. Simultaneously, there sales are also expected to increase due to profit erosion of presently available therapeutics. In this way, newly introduced multiple myeloma therapeutics are expected to increase several folds in coming years. Besides this, more patients are willing to pay for such therapeutics which can increase their disease free progression.

“Global Multiple Myeloma Drug Market & Pipeline Insight 2015” Report Highlight:

  • Global Multiple Myeloma Drug Market Analysis
  • Global Multiple Myeloma Drug Clinical Insight by Company, Indication & Phase
  • Marketed Multiple Myeloma Drugs Clinical Insight
  • Mechanism of Multiple Myeloma Drug
  • Global Multiple Myeloma Drug Clinical Pipeline: 164 Drugs
  • Majority Multiple Myeloma Drugs in Phase-II Trials: 40
  • Marketed Multiple Myeloma Drugs: 9

Table of Contents

1. Introduction to Multiple Myeloma

2. Mechanism of Multiple Myeloma Drug

3. Global Multiple Myeloma Drug Market Analysis

  • 3.1. Current Market Scenario
  • 3.2. Multiple Myeloma Drug Clinical Pipeline Overview

4. Global Multiple Myeloma Drug Market Dynamics

  • 4.1. Favorable Market Parameters
  • 4.2. Commercialization Challenges

5. Global Multiple Myeloma Drug Market Future Prospects

6. Global Multiple Myeloma Drug Clinical Insight by Company, Indication & Phase

  • 6.1. Research
  • 6.2. Preclinical
  • 6.3. Clinical
  • 6.4. Phase-I
  • 6.5. Phase-I/II
  • 6.6. Phase-II
  • 6.7. Phase-III
  • 6.8. Preregistration

7. Marketed Multiple Myeloma Drugs Clinical Insight

  • 7.1. Bendamustine (Innomustine® Levact®, Treanda® & Treakisym®)
  • 7.2. Bortezomib (Velcade®)
  • 7.3. Carfilzomib (Kyprolis®)
  • 7.4. Doxorubicin Liposomal - ALZA
  • 7.5. Interferon Alpha-2b (Intron® A)
  • 7.6. Lenalidomide (Ladevina® & Revlimid®)
  • 7.7. Pomalidomide (Imnovid® & Pomalyst®)
  • 7.8. Thalidomide (Thaled®, Thalidomide Celgene™ & Thalomid®)
  • 7.9. Zoledronic Acid (Zometa®)

8. Discontinued & Suspended Multiple Myeloma Drugs in Clinical Pipeline

  • 8.1. No Development Reported
  • 8.2. Discontinued
  • 8.3. Suspended

9. Competitive Landscape

  • 9.1. AbbVie
  • 9.2. Altor BioScience
  • 9.3. Astellas Pharma
  • 9.4. Astex Pharmaceuticals
  • 9.5. Benovus Bio
  • 9.6. Biogen Idec
  • 9.7. Bristol-Myers Squibb
  • 9.8. Celegen Pharmaceuticals
  • 9.9. Cleave Biosciences
  • 9.10. Genmab
  • 9.11. Novartis
  • 9.12. Onyx Pharmaceuticals
  • 9.13. Pfizer
  • 9.14. Millennium Pharmaceuticals
  • 9.15. Vaxil Biotherapeutics

List of Figures

  • Figure 1-1: Type of Blood Cancer
  • Figure 1-2: Development of Multiple Myeloma in Body
  • Figure 1-3: Causes of Multiple Myeloma
  • Figure 1-4: Symptoms of Multiple Myeloma
  • Figure 2-1: Diagnosis of Multiple Myeloma
  • Figure 2-2: Stages of Multiple Myeloma
  • Figure 2-3: Treatments Available for Multiple Myeloma
  • Figure 2-4: Mechanism of Doxorubicin
  • Figure 2-5: Mechanism of MAGE-A3 Vaccine
  • Figure 2-6: Mechanism of Carfilzomib
  • Figure 3-1: Global Multiple Myeloma Drug Market Size (US$ Billion), 2015-2019
  • Figure 3-2: Multiple Myeloma Drug Pipeline by Phase (%), 2015
  • Figure 3-3: Multiple Myeloma Drug Pipeline by Phase (Number), 2015
  • Figure 3-4: No Development Reported in Multiple Myeloma Drug Pipeline by Phase (%), 2015
  • Figure 3-5: No Development Reported in Multiple Myeloma Drug Pipeline by Phase (Number), 2015
  • Figure 3-6: Discontinued Multiple Myeloma Drug Pipeline by Phase (%), 2015
  • Figure 3-7: Discontinued Multiple Myeloma Drug Pipeline by Phase (Number), 2015
  • Figure 3-8: Suspended Multiple Myeloma Drug Pipeline by Phase (%), 2015
  • Figure 3-9: Suspended Multiple Myeloma Drug Pipeline by Phase (Number), 2015
  • Figure 4-1: Global Multiple Myeloma Drug Market Favorable Parameters
  • Figure 4-2: Global Multiple Myeloma Drug Commercialization Challenges
  • Figure 9-1: Altor BioScience Clincal Pipeline
  • Figure 9-2: Astex Pharmaceuticals Clincal Pipeline
  • Figure 9-3: Benovus Bio Clincal Pipeline
  • Figure 9-4: Genmab Clincal Pipeline
  • Figure 9-5: Onyx Pharmaceuticals Clinical Pipeline
Back to Top